ArticleScientific reports2026
Protective structural and enzymatic roles of catechin and gallic acid against nephrotoxicity and hepatotoxicity ınduced by cisplatin.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rupatadine Ameliorates Cisplatin-Induced Hepatotoxicity in Rats: Targeting HMGB1/TLR4/NF-κB and NLRP3/Caspase-1 Signaling Pathways.Journal of biochemical and molecular toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to investigate the structural and enzymatic effects of Catechin (K) and gallic acid (G) in the treatment of nephrotoxicity and hepatotoxicity induced by cisplatin. Cisplatin (cis-[Pt(NH3)2Cl2]), while commonly used as a cancer treatment, can have toxic effects on the kidneys and liver. In the study, cisplatin (15 mg/kg) was administered intraperitoneally to rats to induce toxicity, and then Catechin (C15H14O6) (20 mg/kg) and gallic acid (3,4,5-Trihydroxybenzoic acid) (100 mg/kg) were administered by oral gavage for 4 weeks. The experimental results showed that cisplatin treatment caused a loss of body weight, as well as reductions in kidney and liver weights. Significant damage to kidney and liver tissues was observed, along with increased serum levels of urea, creatinine, BUN, AST, ALT, and tissue levels of MDA. Additionally, increased levels of GPx and GSR were recorded. The results suggest that catechin and gallic acid significantly ameliorate cisplatin-induced kidney and liver damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.